Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355573 | 0.88 | MAPK1 (0.66) | HSD17B10MAPK1HTTSMN1; SMN2HRH3 | |
| SCHEMBL14000496 | 0.87 | MAPK1 (0.64) | HSD17B10MAPK1HTTHRH3KCNH2 | |
| SCHEMBL7762886 | 0.85 | HSD17B10 (0.72) | HSD17B10MAPK1HTTSMN1; SMN2THRB | |
| SCHEMBL14000477 | 0.84 | MAPK1 (0.60) | HSD17B10MAPK1HTTHRH3POLB | |
| SCHEMBL3724649 | 0.84 | POLB (0.70) | HSD17B10MAPK1HTTHRH3POLB | |
| SCHEMBL23874011 | 0.84 | ESR1 (0.67) | HSD17B10MAPK1HTTRECQLKDM4E | |
| SCHEMBL120600 | 0.84 | HSD17B10 (1.00) | HSD17B10MAPK1HTTSMN1; SMN2THRB | |
| SCHEMBL13666576 | 0.84 | HSD17B10 (0.79) | HSD17B10MAPK1HTTSMN1; SMN2THRB | |
| SCHEMBL29784251 | 0.84 | HSD17B10 (1.00) | HSD17B10MAPK1HTTSMN1; SMN2THRB | |
| SCHEMBL540947 | 0.84 | MAPK1 (1.00) | HSD17B10MAPK1HTTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109735242-B | Easy-to-tear woven adhesive tape and preparation method thereof | 宁波三同编织有限公司 | 2021-02-12 | — | — | CN | claimed |
| CN-109735242-B | Easy-to-tear woven adhesive tape and preparation method thereof | 宁波三同编织有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008045371-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | HNMT, HRH4, HRH3 | HSD17B10 3575/4885MAPK1 2641/4885HTT 378/4885 |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HSD17B10 2810/4885MAPK1 3167/4885HTT 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.